Masterarbeit
Finding a balance between the need for comprehensive transparency in clinical trials and the protection of commercially confidential information in today’s regulatory environment
Eva Kreßner (2024)
Summary
Language: English
The thesis titled
"Finding a balance between the need for comprehensive transparency in
clinical trials and the protection of commercially confidential
information in today’s regulatory environment" focuses on navigating the
complex relationship between transparency and the protection of
commercially confidential information (CCI) in clinical trials,
particularly under the European Union's Clinical Trials Regulation (EU
CTR) No 536/2014. The thesis addresses the conflicting expectations of
key stakeholders, such as sponsors and patients, in clinical trials.
Clinical
trials are vital for advancing medical knowledge and developing new
therapies. However, the need for transparency to maintain scientific
integrity and public trust often conflicts with the need to protect CCI.
Sponsors aim to secure marketing authorizations and safeguard trade
secrets, while patients demand access to information about new treatment
options. The EU CTR, effective from January 2022, seeks to harmonize
clinical trial approval processes across EU member states and the
European Economic Area (EEA), enhancing transparency and participant
safety.
This thesis concludes that while the EU CTR has made
significant strides in promoting transparency, challenges remain,
particularly in protecting CCI and ensuring stakeholder compliance. It
recommends the following:
- Improved Regulatory Compliance: Streamlining administrative processes and in-vesting in digital infrastructure to enhance regulatory compliance and reduce burdens on stakeholders.
- Stakeholder Engagement: Encouraging active engagement with patients, advocacy groups, and the public to build trust and improve understanding of clinical trials.
- Balanced Approach to CCI: Developing guidelines to protect CCI while ensuring transparency, fostering a culture of openness without compromising economic interests.
- Continued Evolution of Transparency Practices: Emphasizing the need for ongoing updates and refinements to transparency guidelines, considering emerging challenges and innovations in clinical research.
Pages: 97
Annexes: 01, Pages: 05